Show simple item record

dc.contributor.advisorHutt, Peter Bartonen_US
dc.contributor.authorPierce, Gregory D.en_US
dc.date.accessioned2012-06-07T01:54:44Z
dc.date.issued1995en_US
dc.identifier.citationRegulating the Export of Unapproved Drugs (1995 Third Year Paper)en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8846729
dc.description.abstractPrior to 1986, it was not possible under the Federal Food Drug and Cosmetics Act to export drugs which did not have FDA approval. The law was changed by the Drug Export Amendments Act of 1986 after nearly a decade of debate. Those who favored liberalizing the drug export law argued that American companies were at a competitive disadvantage in foreign markets because of the prohibitions, and the pharmaceutical industry suffered as a result. They argued that the national sovereignty of those countries that decided that unapproved drugs were appropriate for use by their citizens should be respected, and that it would be excessively paternalistic to deny these countries the products they desired. Those who opposed lifting the ban on exporting unapproved drugs argued that economic concerns were not sufficient to overcome the ethical difficulty in creating a double standard which allowed drugs that had not been determined safe and effective for use by U.S. citizens to be used by the citizens of foreign nations.en
dc.language.isoen_USen
dash.licenseLAAen_US
dc.subjectFood and Drug Lawen
dc.subjectdrug exportationen
dc.titleRegulating the Export of Unapproved Drugsen
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-06-07T01:54:44Z
dash.authorsorderedfalse


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record